← Back to Search
Once-monthly Oral Ibandronate Improves Biomechanical Determinants Of Bone Strength In Women With Postmenopausal Osteoporosis.
E. Lewiecki, T. M. Keaveny, D. Kopperdahl, H. Genant, K. Engelke, T. Fuerst, A. Kivitz, R. Davies, L. Fitzpatrick
Published 2009 · Medicine
Download PDFAnalyze on Scholarcy
CONTEXT Bone strength and fracture resistance are determined by bone mineral density (BMD) and structural, mechanical, and geometric properties of bone. DESIGN, SETTING, AND OBJECTIVES: This randomized, double-blind, placebo-controlled outpatient study evaluated effects of once-monthly oral ibandronate on hip and lumbar spine BMD and calculated strength using quantitative computed tomography (QCT) with finite element analysis (FEA) and dual-energy x-ray absorptiometry (DXA) with hip structural analysis (HSA). PARTICIPANTS Participants were women aged 55-80 yr with BMD T-scores -2.0 or less to -5.0 or greater (n = 93). INTERVENTION Oral ibandronate 150 mg/month (n = 47) or placebo (n = 46) was administered for 12 months. OUTCOME MEASURES The primary end point was total hip QCT BMD change from baseline; secondary end points included other QCT BMD sites, FEA, DXA, areal BMD, and HSA. All analyses were exploratory, with post hoc P values. RESULTS Ibandronate increased integral total hip QCT BMD and DXA areal BMD more than placebo at 12 months (treatment differences: 2.2%, P = 0.005; 2.0%, P = 0.003). FEA-derived hip strength to density ratio and femoral, peripheral, and trabecular strength increased with ibandronate vs. placebo (treatment differences: 4.1%, P < 0.001; 5.9%, P < 0.001; 2.5%, P = 0.011; 3.5%, P = 0.003, respectively). Ibandronate improved vertebral, peripheral, and trabecular strength and anteroposterior bending stiffness vs. placebo [7.1% (P < 0.001), 7.8% (P < 0.001), 5.6% (P = 0.023), and 6.3% (P < 0.001), respectively]. HSA-estimated femoral narrow neck cross-sectional area and moment of inertia and outer diameter increased with ibandronate vs. placebo (respectively 3.6%, P = 0.003; 4.0%, P = 0.052; 2.2%, P = 0.049). CONCLUSIONS Once-monthly oral Ibandronate for 12 months improved hip and spine BMD measured by QCT and DXA and strength estimated by FEA of QCT scans.
This paper references
Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database.
N. Watts (2004)
Severity of vertebral fracture reflects deterioration of bone microarchitecture
H. Genant (2006)
Finite element models predict in vitro vertebral body compressive strength better than quantitative computed tomography.
R. Crawford (2003)
Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women.
K. Uusi-Rasi (2005)
Effects of ibandronate on bone quality: preclinical studies.
F. Bauss (2007)
Effects of Intravenous Zoledronic Acid Once Yearly on Bone Remodeling and Bone Structure
R. Recker (2008)
Effect of risedronate on hip structural geometry: a 1-year, double-blind trial in chemotherapy-induced postmenopausal women.
G.J. van Londen (2008)
Impact direction from a fall influences the failure load of the proximal femur as much as age-related bone loss
T. Pinilla (2006)
Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study
R. Recker (2003)
Structural and remodeling indices in the cancellous bone of the proximal femur across adulthood.
H. Tsangari (2007)
Considerations for Development of Surrogate Endpoints for Antifracture Efficacy of New Treatments in Osteoporosis: A Perspective
M. Bouxsein (2008)
Comparison of DXA hip structural analysis with volumetric QCT.
T. Beck (2009)
How can bone turnover modify bone strength independent of bone mass?
C. Hernandez (2008)
Improved prediction of proximal femoral fracture load using nonlinear finite element models.
J. Keyak (2001)
Effect of Hormone Replacement, Alendronate, or Combination Therapy on Hip Structural Geometry: A 3‐Year, Double‐Blind, Placebo‐Controlled Clinical Trial
S. Greenspan (2005)
Alterations of Cortical and Trabecular Architecture Are Associated With Fractures in Postmenopausal Women, Partially Independent of Decreased BMD Measured by DXA: The OFELY Study
E. Sornay-Rendu (2007)
A biomechanical perspective on bone quality.
C. Hernandez (2006)
Structural Determinants of Vertebral Fracture Risk
L. J. Melton (2007)
Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies*
S. Harris (2008)
Risedronate Preserves Trabecular Architecture and Increases Bone Strength in Vertebra of Ovariectomized Minipigs as Measured by Three‐Dimensional Microcomputed Tomography
B. Borah (2002)
Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The risedronate and alendronate (REAL) cohort study
S. Silverman (2006)
Clinical use of quantitative computed tomography and peripheral quantitative computed tomography in the management of osteoporosis in adults: the 2007 ISCD Official Positions.
K. Engelke (2008)
Structural Trends in the Aging Femoral Neck and Proximal Shaft: Analysis of the Third National Health and Nutrition Examination Survey Dual‐Energy X‐Ray Absorptiometry Data
T. J. Beck (2000)
A Biomechanical Analysis of the Effects of Resorption Cavities on Cancellous Bone Strength
C. Hernandez (2006)
An anatomic coordinate system of the femoral neck for highly reproducible BMD measurements using 3D QCT.
Yan Kang (2005)
Is cortical bone hip? What determines cortical bone properties?
S. Epstein (2007)
Cortical and Trabecular Load Sharing in the Human Vertebral Body
S. Eswaran (2006)
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.
M. Mcclung (2001)
Volumetric quantitative computed tomography of the proximal femur: relationships linking geometric and densitometric variables to bone strength. Role for compact bone
V. Bousson (2006)
Sex differences in age-related changes in vertebral body size, density and biomechanical competence in normal individuals.
L. Mosekilde (1990)
Cancellous bone remodeling in type i (postmenopausal) osteoporosis: Quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels
Erik F. Eriksen (1990)
Long‐Term Protective Effects of Zoledronic Acid on Cancellous and Cortical Bone in the Ovariectomized Rat
J. Gasser (2008)
Femoral Bone Strength and Its Relation to Cortical and Trabecular Changes After Treatment With PTH, Alendronate, and Their Combination as Assessed by Finite Element Analysis of Quantitative CT Scans
T. M. Keaveny (2008)
HSA: beyond BMD with DXA.
S. Bonnick (2007)
68 Regional Differences of Spinal BMD Changes After One Year Once-Monthly Ibandronate as Measured by 3D QCT
Klaus Engelke (2009)
A hierarchical 3D segmentation method and the definition of vertebral body coordinate systems for QCT of the lumbar spine
André Mastmeyer (2006)
Effect of oral ibandronate on hip structure: results from the BONE study [abstract Su323]
T Fuerst (2006)
Effects of Teriparatide and Alendronate on Vertebral Strength as Assessed by Finite Element Modeling of QCT Scans in Women With Osteoporosis
T. M. Keaveny (2007)
Finite Element Analysis of the Proximal Femur and Hip Fracture Risk in Older Men
E. Orwoll (2009)
This paper is referenced by
Can hip fracture prediction in women be estimated beyond bone mineral density measurement alone?
P. Geusens (2010)
Impact of oral ibandronate 150 mg once monthly on bone structure and density in post-menopausal osteoporosis or osteopenia derived from in vivo μCT.
O. Bock (2012)
Efficacy and Safety of Monthly 150 mg Oral Ibandronate in Women with Postmenopausal Osteoporosis: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Y. Lee (2011)
Assessment of finite element models for prediction of osteoporotic fracture.
Yeokyeong Lee (2019)
Higher doses of bisphosphonates further improve bone mass, architecture, and strength but not the tissue material properties in aged rats.
M. Shahnazari (2010)
Prevention and treatment of postmenopausal osteoporosis
A. Neuprez (2010)
Quantitative computed tomography assessment of bone mineral density after 2 years’ oral bisphosphonate treatment in postmenopausal osteoarthritis patients who underwent total knee arthroplasty
Jin Kyu Lee (2013)
Biomechanical modeling of proximal femur : development of finite element models to simulate fractures
Janne Koivumäki (2013)
Skeletal assessment with finite element analysis: relevance, pitfalls and interpretation
Graeme M Campbell (2017)
Use of DXA‐based finite element analysis of the proximal femur in a longitudinal study of hip fracture
K. Naylor (2013)
A comparison of DXA and CT based methods for estimating the strength of the femoral neck in post-menopausal women
M. Danielson (2012)
Quantifying the material and structural determinants of bone strength.
M. Bouxsein (2009)
Advanced CT based In Vivo Methods for the Assessment of Bone Density, Structure, and Strength
K. Engelke (2013)
Fracture Risk Prediction by Non-BMD DXA Measures: the 2015 ISCD Official Positions Part 1: Hip Geometry.
S. Broy (2015)
Age-Dependence of Femoral Strength in White Women and Men
T. M. Keaveny (2010)
RELATIONSHIPS OF LONG-TERM BISPHOSPHONATE TREATMENT WITH MEASURES OF BONE MICROARCHITECTURE AND MECHANICAL COMPETENCE
J. J. Ward (2014)
Effect of Ibandronate on Bending Strength and Toughness on Rodent Cortical bone ; possible implications for fracture prevention
R. Wallace (2015)
Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene
F. Cosman (2013)
Fracture ostéoporotique chez l'homme : estimation du risque en tomodensitométrie à la hanche
J. Lellouche (2015)
Effects of strontium ranelate and alendronate on bone microstructure in women with osteoporosis
R. Rizzoli (2011)
Les apports de la DXA en dehors de la mesure de la densité minérale osseuse
Karine Briot (2013)
Hip Fracture Discrimination Based on Statistical Multi-parametric Modeling (SMPM)
J. Carballido-Gamio (2019)
Atlas of Postmenopausal Osteoporosis
R. Rizzoli (2010)
Femoral strength in osteoporotic women treated with teriparatide or alendronate.
T. M. Keaveny (2012)
Effect of ibandronate on bending strength and toughness of rodent cortical bone
T. Savaridas (2015)
Influence of 3D QCT scan protocol on the QCT-based finite element models of human vertebral cancellous bone.
Yongtao Lu (2014)
Comparison of proximal femur and vertebral body strength improvements in the FREEDOM trial using an alternative finite element methodology.
P. Zysset (2015)
Association of incident hip fracture with the estimated femoral strength by finite element analysis of DXA scans in the Osteoporotic Fractures in Men (MrOS) study
L. Yang (2017)
Vertebral Strength Changes as Assessed by Finite Element Analysis
T Mawatari (2016)
Distribution of bone density and cortical thickness in the proximal femur and their association with hip fracture in postmenopausal women: a quantitative computed tomography study
L. Yang (2013)
Clinical Use of Quantitative Computed Tomography (QCT) of the Hip in the Management of Osteoporosis in Adults: the 2015 ISCD Official Positions-Part I.
K. Engelke (2015)
Quantitative Computed Tomography-Current Status and New Developments.
K. Engelke (2017)See more